Latest Car T News

Sena & Co, already holding 75.9% of 2 Cheap Cars, proposes a full takeover at NZ$0.80 per share, aiming to delist the company and compulsorily acquire remaining shares.

Imugene's azer-cel therapy shows a third patient response in the BTKi combination cohort of its Phase 1b trial, while CEO Leslie Chong steps down after nearly 11 years, prompting a leadership search.

Australian Foundation Investment Company (ASX:AFI) posted a 3% increase in net profit for FY26, holding dividends steady with a special payout amid portfolio underperformance against the ASX 200.

The Star Entertainment Group reported a significant improvement in quarterly EBITDA loss alongside stable revenue, completing key joint venture exit and refinancing milestones that boosted liquidity to $267 million.

Mirrabooka Investments reported a 63.6% jump in net profit to $13 million for FY26, boosted by higher investment income and dividends. However, its portfolio lagged the benchmark, dragged down by sector exposures and tech stock de-ratings.

Chimeric Therapeutics reports encouraging interim data from its Phase 1/2 trial of CHM CDH17 CAR-T therapy, with tumour shrinkage up to 40% and stable disease maintained for months at the highest dose level.

BHP delivered record iron ore volumes and stable copper production of around 2 million tonnes in FY26, underpinned by disciplined cost control and a robust growth pipeline including the Ministers North project.

INOVIQ Ltd has revealed significant sample quality problems in its EXO-OC ovarian cancer diagnostic study, prompting a technical review and a refined development approach while maintaining its dual commercialisation strategy.

INOVIQ Limited hit a roadblock in expanding clinical validation of its EXO-OC™ ovarian cancer test due to unsuitable biobank samples, yet improved its diagnostic algorithm and progressed its CAR-exosome therapeutic program, maintaining a solid cash position of A$9.35 million.

Sena & Co Limited has launched a conditional full takeover offer for the remaining shares of 2 Cheap Cars Group Limited, aiming to increase its stake from 75.9% to at least 90%. The NZ$0.80 per share cash offer comes with plans to delist 2CC and maintain current operations.

Jumbo Interactive updates its FY26 earnings outlook, trimming EBITDA guidance for its UK acquisition while significantly upgrading US business forecasts, amid ongoing integration and leadership changes.

Imugene has secured $11.12 million through a placement to advance its allogeneic CAR-T therapy azer-cel after early clinical data showed complete responses in BTKi-resistant lymphoma patients.